For example, the rigorous CF daily treatment regime, stringent infection control guidelines precluding face-to-face contact between those with CF (Muther et al., 2018), and cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs, the most recent of which (elexacaftor/tezacaftor/ivacaftor, Trikafta®, Vertex Pharmaceuticals Incorporated) have demonstrated transformative quality-of-life and physical health outcomes (Finlay et al., 2022; Havermans & Duff, 2020; Schechter et al., 2021). The gene discussed is CFTR; the disease is infection.